Pharmafile Logo
Pharmafocus logo
Advanced Search

Vyxeos

Showing 5 posts of 5 posts found.

jazz_pharma

Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia

November 8, 2018
Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma

Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …

News
jazz_pharma

Jazz Pharma’s acute myeloid leukaemia drug scores EU approval

August 29, 2018
Research and Development, Sales and Marketing Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, leukaemia, pharma

Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …

News

Jazz Pharmaceuticals to acquire Celator in $1.5 billion deal

May 31, 2016
Manufacturing and Production, Sales and Marketing $1.5 billion, Vyxeos, acquisition, celator, jazz, leukaemia, merger, oncology

Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that it has entered into a definitive merger agreement with Celator Pharmaceuticals (NASDAQ: CPXX) …

News
clinical_trial_3

Celator receives FDA breakthrough therapy designation for leukaemia drug

May 20, 2016
Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator

A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …

News
celatorpharmalogo

Celator’s shares jump on positive late-stage trials for leukaemia drug

March 16, 2016
Business Services, Research and Development, Sales and Marketing Celator Pharmaceuticals, EMA, US FDA, Vyxeos, drug trials, phase III

Shares in trial-stage Celator Pharmaceuticals (Nasdaq: CPXX) soared gaining over four times in value as the company announced late-stage trials …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026